Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure

The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Veterinary Medical Science 2017, Vol.79(1), pp.29-34
Main Authors: MIZUNO, Masashi, YAMANO, Shigeki, CHIMURA, Shuichi, HIRAKAWA, Atsushi, TAKUSAGAWA, Yoshimi, SAWADA, Tamotsu, MAETANI, Shigeki, TAKAHASHI, Arane, MIZUNO, Takeshi, HARADA, Kayoko, SHINODA, Asako, UCHIDA, Shuhei, TAKEUCHI, Junichiro, MIZUKOSHI, Takahiro, ENDO, Masaaki, UECHI, Masami
Format: Article
Language:English
Subjects:
angiotensin-converting enzyme inhibitor
Animals
calcium sensitizer
canine
Cardiotonic Agents - therapeutic use
Congestive heart failure
Dog Diseases - mortality
Dog Diseases - prevention & control
Dogs
Edema
Female
Heart failure
Heart Failure - etiology
Heart Failure - mortality
Heart Failure - prevention & control
Heart Failure - veterinary
Hospitals
Internal Medicine
Male
mitral regurgitation
Mitral valve
Mitral Valve Insufficiency - complications
Mitral Valve Insufficiency - drug therapy
Mitral Valve Insufficiency - mortality
Mitral Valve Insufficiency - veterinary
Pulmonary Edema - etiology
Pulmonary Edema - mortality
Pulmonary Edema - prevention & control
Pulmonary Edema - veterinary
Pyridazines - therapeutic use
Recurrence
Retrospective Studies
Rheumatic heart disease
Survival
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without pimobendan. Sixty-four dogs received a standard dose of pimobendan (0.20–0.48 mg/kg every 12 hr (q12hr)), 49 dogs received a low dose of pimobendan (0.05–0.19 mg/kg q12hr), and 84 dogs received conventional therapy alone. Dogs in the standard-dose and low-dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P
ISSN:0916-7250
1347-7439
DOI:10.1292/jvms.16-0069